INSERM - UMR866 - Centre de recherche

Groeneveld C, Sanchez-Quiles V, Dufour F, Shi M, Dingli F, Gentric G, Nicolle R, Chapeaublanc E, Poullet P, Vacherot F, Benhamou S, Lebret T, Micheau O, Mechta-Grigoriou F, Zinovyev A, Loew D, Allory Y, de Reyniès A, Bernard-Pierrot I, Radvanyi F. Proteogenomic characterization of bladder cancer reveals sensitivity to TRAIL-induced apoptosis in FGFR3-mutated tumors. European Urology 2023, accepted for publication.
Radoua A, Pernon B, Pernet N, Jean C, Elmallah M, Guerrache A, Constantinescu AA, Hadj Hamou S, Devy J, Micheau O. ptARgenOM - a flexible vector for CRISPR/CAS9 non-viral delivery Small Methods 2023, 2300069.
Ichim G, Gibert B, Adriouch S, Brenner C, Davoust N, Desagher S, Devos D, Dokudovskaya S, Dubrez L, Estaquier J, Gillet G, Guénal I, Juin PP, Kroemer G, Legembre P, Levayer R, Manon S, Mehlen P, Meurette O, Micheau O, Mignotte B, Nguyen-Khac F, Popgeorgiev N, Poyet JL, Priault M, Ricci JE, Riquet FB, Susin SA, Suzanne M, Vacher P, Walter L, Mollereau B. Keeping Cell Death Alive: An Introduction into the French Cell Death Research Network. 2022 Biomolecules 12(7):901-929.
Zischler L, Cogo SC, Micheau O, Elifio-Esposito S. Evidence that BJcuL, a C-type lectin from Bothrops jararacussu venom, influences deubiquitinase activity, resulting in the accumulation of anti-apoptotic proteins in two colorectal cancer cell lines. 2022 Int. J. Macromol. 209(Pt A):1205-1210.
Airiau K, Vacher P, Micheau O, Prouzet-Mauleon V, Kroemer G, Moosavi MA, Djavaheri-Mergny M. TRAIL Triggers CRAC-Dependent Calcium Influx and Apoptosis through the Recruitment of Autophagy Proteins to Death-Inducing Signaling Complex. 2022 Cells 11(1):57.
Abdelkafi-Koubaa Z, ELBini-Dhouib I, Souid S, Jebali J, Doghri R, Srairi-Abid N, Essafi-Benkhadir K, Micheau O, Marrakchi N. Pharmacological Investigation of CC-LAAO, an L-Amino Acid Oxidase from Cerastes cerastes Snake Venom. 2021 Toxins 13(12):904.
Micheau O, Rizzi M, Smulski C. Editorial: TNFR Superfamily Oligomerization and Signaling. 2021 Front. Cell Dev. Biol. 9:682472.
Montfort A, Bertrand F, Rochotte J, Gilhodes J, Filleron T, Milhès J, Dufau C, Imbert C, Riond J, Tosolini M, Clarke CJ, Dufour F, Constantinescu AA, de França Junior N, Garcia V, Record M, Cordelier P, Brousset P, Rochaix P, Silvente-Poirot S, Therville N, Andrieu-Abadie N, Levade T, Hannun YA, Benoist H, Meyer N, Micheau O, Colacios C, Ségui B. Neutral sphingomyelinase 2 heightens anti-melanoma immune responses and anti-PD-1 therapy efficacy 2021 Cancer Immunol Res. 9(5):568-582.
Belkahla H, Constantinescu AA, Gharbi T, Barbault F, Chevillot-Biraud A, Decorse P, Micheau O, Hemadi M*, Ammar S* Grafting TRAIL through either Amino or Carboxylic Groups onto Maghemite Nanoparticles: Influence on Pro-Apoptotic Efficiency 2021 Nanomaterials 11(2), 502.
Cardoso Alves L, Corazza N, Micheau O, Krebs P. The multifaceted role of TRAIL signaling in cancer and immunity. 2020 FEBS J 288(19):5530-5554.
Vanbervliet-Defrance B, Delaunay T, Daunizeau T, Kepenekian V, Glehen O, Weber K, Estornes Y, Ziverec A, Djemal L, Delphin M, Lantuéjoul S, Passot G, Grégoire M, Micheau O, Blanquart C, Renno T, Fonteneau JF, Lebecque S, Mahtouk K. Cisplatin unleashes Toll-like receptor 3-mediated apoptosis through the downregulation of c-FLIP in malignant mesothelioma. 2020 Cancer Letters, 472:29-39.
Elmallah MIY, Cogo S, Constantinescu AA, Elifio-Esposito S, Abdelfattah MS, Micheau O. Marine Actinomycetes-Derived Secondary Metabolites Overcome TRAIL-Resistance via the Intrinsic Pathway through Downregulation of Survivin and XIAP. 2020 Cells 9(8):E1760.
Elmallah MIY, Micheau O. Epigenetic Regulation of TRAIL Signaling: Implication for Cancer Therapy. 2019 Cancers, This article belongs to the Special Issue TRAIL Signaling in Cancer Cells
Belkahla H, Mazario E, Plan Sangnier A, Lomas JS, Gharbi T, Ammar S, Micheau O*, Wilhem C*, Hemadi M* TRAIL acts synergistically with iron oxide nanoclusters-mediated magneto- and photothermia. (* co-corresponding). 2019 Theranostics 9(20):5924-5936
Dubuisson A, Favreau C, Fourmaux E, Lareure S, Rodrigues-Saraiva R, Pellat-Deceunynck C, El Alaoui S, Micheau O. Generation and characterization of novel anti-DR4 and anti-DR5 antibodies developed by genetic immunization. 2019 Cell Death Dis.10(2):101.
Belkahla H, Haque A, Revzin A, Gharbi T, Constantinescu AA, Micheau O*, Hemadi M, Ammar S* Coupling TRAIL to iron oxide nanoparticles increases its apoptotic activity on HCT116 and HepG2 cells. Effect of the magnetic core size. . (* co-corresponding). 2019 JOIN 2:55
Brown P; RELISH Consortium (Micheau O.), Zhou Y. Large expert-curated database for benchmarking document similarity detection in biomedical literature search. 2019 Database (Oxford) baz085
Alkurdi L, Virard F, Vanbervliet B, Weber K, Toscano F, Bonnin M, Le Stang N, Lantuejoul S, Micheau O, Renno T, Lebecque S, Estornes Y. Release of c-FLIP brake selectively sensitizes human cancer cells to TLR3-mediated apoptosis. 2018 Cell Death Dis. 9(9):874.
Vial J, Royet A, Cassier P, Tortereau A, Dinvaut S, Maillet D, Gratadou-Hupon L, Creveaux M, Sadier A, Tondeur G, Léon S, Depaepe L, Pantalacci S, De la Fouchardiere A, Micheau O, Dalle S, Laudet V, Mehlen P, Castets M. The Ectodysplasin Receptor EDAR acts as a tumor suppressor in melanoma by conditionally inducing cell death. Cell Death Differ. 26(3):443-454.
Micheau O. Regulation of TNF-Related Apoptosis-Inducing Ligand Signaling by Glycosylation. 2018 Int. J Mol. Sci. 19(3). pii: E715 MDPI.
Chekkat N, Lombardo CM, Seguin C, Lechner MC, Dufour F, Nominé Y, De Giorgi M, Frisch B, Micheau O, Guichard G, Altschuh D, Fournel S. Relationship between the agonist activity of synthetic ligands of TRAIL-R2 and their cell surface binding modes. 2018 Oncotarget, e24526.
Dubuisson A, Micheau O. Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy. 2017 Antibodies, 6(4), 16. MDPI.
Micheau O. Posttranslational Modifications and Death Receptor Signalling. 2017 Resistance to Targeted Anti-Cancer Therapeutics book (Ed. O Micheau), pp247-290. Chapter.Acces to the BOOK.
Belkahla H, Herlem G, Picaud F, Gharbi T, Hémadi M, Ammar S, Micheau O. TRAIL-NP hybrids for cancer therapy: A review. 2017 Nanoscale, 9(18):5755-5768. Pubmed.
Glorian V, Allegre J, berthelet J, Dumetier B, Betanquoi PM, Droin N, Kayaci C, Cartier J, Gemble S, Garcion G, Gonzalez D, Boidot R, Garrido C, Micheau O, Solary E, Dubrez L. cIAP1-mediated E2F1 stabilization and transcriptional activation involve K63-poly-ubiquitination. 2017 Cell Death Dis., 8(5):e2816 / 9(8):785. Pubmed.
Dufour F, Rattier T, Constantinescu AA, Zischler L, Morlé A, Ben Mabrouk H, Humblin E, Jacquemin G, Szegezdi E, Delacote F, Marrakchi N, Guichard G, Gharbi T, Pellat-Deceunynck C, Vacher P, Legembre P, Garrido C, Micheau O. TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress. 2017 Oncotarget. 8(6), pp 9974-9985. Pubmed
Constantinescu AA, Morlé A, Micheau O. Immunoprecipitation of Death Inducing Signaling Complex by Caspase-8. 2017 Methods Mol Biol. 1557:19-31. Pubmed
Dufour F, Rattier T, shirley S, Picarda G, Morlé A, Zakaria AB, Marcion G, Causse S, Szegezdi E, Zajonc DM, Seigneuric R, Guichard G, Picaud F, Herlem G, Garrido C, Schneider P, Benedict CA, Micheau O. N-glycosylation regulates cell death induced by mouse TRAIL-R and human TRAIL-R1. 2017 Cell Death Differ. 24(3), pp 500-510. Pubmed
Micheau O. FLIP. In: Marshall JL (ed.). 2016 Cancer Therapeutic Targets. pp881-891. Springer, New York
Abassi H, Ayed-Boussema I, Shirley S, Abid S, Bacha H, Micheau O. The mycotoxin zearalenone enhances cell proliferation, colony formation and promotes cell migration in the human colon carcinoma cell line HCT116. 2016 Toxicol Lett. 254, pp 1-7. Pubmed
Elmallah MIY, Micheau O., Eid MAG, Hebishy AMS, Abdelfattah MS Marine actinomycete crude extracts with potent TRAIL-resistance overcoming activity against breast cancer cells. 2017 Oncol Rep. 37(6), pp 3635-42. Pubmed
Zakaria AB, Guillaume YC, Picaud F, Andre C, Gharbi T, Micheau O, Herlem G. Enhanced DR5 binding capacity of nanovectorized TRAIL compared to its cytotoxic version by affinity chromatography and molecular docking studies. 2016 J of Mol Recognition. 29(9), pp 406-414. Pubmed
Ben Mabrouk H, Zouari-Kessentini R, Montassar F, Abdelkefi-Koubaa Z, Messaadi E, Guillonneau X, El Ayeb M, Srairi-Abid N, Luis J, Micheau O and Marrakchi N. CC5 and CC8, two homologous disintegrins from Cerastes cerastes venom, inhibit in vitro and ex vivo angiogenesis. 2016 Int J of Biol Mol. 86, pp 670-680. Pubmed
Elmallah M.I.Y and Micheau O. Marine Drugs Regulating Apoptosis Induced by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL). 2015 Mar. Drugs, 13(11), pp6884-6909. Pubmed
Legembre P, Micheau O, Segui B. Chemotherapy with ceramide in TNBC. Oncoscience 2(10):817-8. Pubmed
Levade T, Andrieu-Abadie N, Micheau O, Legembre P, Segui B. Sphingolipids modulate the epithelial–mesenchymal transition in cancer. 2015 Cell Death Discovery
Zakaria AB, Picaud F, Duverger E, Devaux X, Delabrousse E, Gharbi T, Micheau O, Herlem G. Nanovector Formation by Functionalization of TRAIL Ligand on Single-walled Carbon Nanotube: Experimental and Theoretical Evidences. 2015 Chem. Phys. Lett, 633, pp 273-281. Pubmed
Iessi E, Zischler L, Etringer A, Bergeret M, Morlé A, Jacquemin G, Morizot A, Shirley S, Lalaoui N, Elifio_esposito SL, Fais S, Garrido C, Solary E, Micheau O. Death receptor-induced apoptosis signalling regulation by Ezrin is cell type dependent and occurs in a DISC-independent manner in colon cancer cells. 2015 PLoS ONE, 10(5): e126526. PubMed
Zakaria AB, Picaud F, Rattier T, Pudlo M, Dufour F, Saviot L, Chassagnon R, Lherminier J, Gharbi T, Herlem G* and Micheau O*. Nanovectorization of TRAIL with single wall carbon nanotubes enhances tumor cell killing. 2015 Nano Letters 15 (2), pp 891–895 (equal contribution) PubMed
Morle A, Garrido C and Micheau O. Hyperthermia restores apoptosis induced by death receptors through aggregation-induced c-FLIP cytosolic depletion. 2015 Cell Death Dis. 6, e1633 PubMed.
Edmond V, Dufour F, Poiroux G, Shoji K, Malleter M, Fouqué A, Tauzin S, Rimokh R, Sergent O, Penna A, Dupuy A, Levade T, Theret N, Micheau O, Ségui B, Legembre P. Downregulation of ceramide synthase-6 during epithelial-to-mesenchymal transition reduces plasma membrane fluidity and cancer cell motility. 2014 Oncogene 34(8):996-1005. Pubmed
de Thonel A, Hazoumé A, Kochin V, Isoniemi K, Jego G, Fourmaux E, Hammann A, Mjahed H, Filhol O, Micheau O, Rocchi P, Mezger V, Eriksson JE, Rangnekar VM, Garrido C. Regulation of the proapoptotic functions of prostate apoptosis response-4 (Par-4) by casein kinase 2 in prostate cancer cells. 2014 Cell Death Dis. 5:e1016. PubMed
Micheau O, Shirley S, Morizot A. TRAIL receptor-induced Regulation : An Update to our deadly DISCussion. 2014 Topics in Anti-Cancer Research, Dr Atta-ur-Rhaman & Khurshid Zaman (Ed.), Vol. 3, 2014, 3-36. Link to Chapter
Micheau O, Shirley S, Dufour F. Death receptors as targets in cancer. 2013 Br J Pharmacol. 169(8):1723-44. PubMed
Estornes Y, Micheau O, Renno T, Lebecque S. Dual Role of TLR3 in Inflammation and Cancer Cell Apoptosis. 2013 Oncogene and Cancer - From Bench to Clinic, Dr. Yahwardiah Siregar (Ed.), ISBN: 978-953-51-0858-0, InTech, DOI: 10.5772/54772. PubMed
Wettstein G, Bellaye PS, Kolb M, Hammann A, Crestani B, Soler P, Marchal-Somme J, Hazoume A, Gauldie J, Gunther A, Micheau O, Gleave M, Camus P, Garrido C, Bonniaud P. Inhibition of HSP27 blocks fibrosis development and EMT features by promoting Snail degradation. 2013 FASEB J. 27(4):1549-60.PubMed
Shirley S and Micheau O Targeting c-FLIP in cancer. 2013 Cancer Letters 332(2):141-50.PubMed
Somasekharan SP, Koc M, Morizot A, Micheau O, Sorensen PH, Gaide O, Andera L, Martinou JC. TRAIL promotes membrane blebbing, detachment and migration of cells displaying a dysfunctional intrinsic pathway of apoptosis. 2013 Apoptosis 18(3):324-36.PubMed
Jennewein C, Karl S, Baumann B, Micheau O, Debatin KM, Fulda S. Identification of a novel pro-apoptotic role of NF-κB in the regulation of TRAIL- and CD95-mediated apoptosis of glioblastoma cells. 2012 Oncogene. 31(11):1468-74. PubMed
Wettstein G, Bellaye PS, Micheau O, Bonniaud P. Small heat shock proteins and the cytoskeleton: an essential interplay for cell integrity? 2012 Int J Biochem Cell Biol. 19(9):1482-94. PubMed
Micheau O, Dufour F, Walczak H. Thiocolchicoside a semi-synthetic derivative of the Glory Lily: a new weapon to fight metastatic bone resorption? 2012 Br J Pharmacol. 44(10):1680-6. PubMed
Estornes Y, Toscano F, Virard F, Jacquemin G, Pierrot A, Vanbervliet B, Bonnin M, Lalaoui N, Mercier-Gouy P, Pacheco Y, Salaun B, Renno T, Micheau O, Lebecque S. dsRNA induces apoptosis through an atypical death complex associating TLR3 to caspase-8. 2012 Cell Death Differ. 19(9):1482-94.PubMed
Jacquemin G, Granci V, Gallouet AS, Lalaoui N, Morlé A, Iessi E, Morizot A, Garrido C, Guillaudeux T, Micheau O Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in Non-Hodgkin B-Lymphoma. 2012 Haematologica 97(1):38-46.PubMed
Shirley S, Morizot A and Micheau O Regulating TRAIL Receptor-Induced Cell Death at the Membrane : A Deadly Discussion. 2011 Recent Pat Anticancer Drug Discov. 6(3):311-23. PubMed
Lalaoui N, Morlé A, Mérino D, Jacquemin G, Iessi E, Morizot A, Shirley S, Robert B, Solary E, Garrido C, Micheau O TRAIL-R4 promotes tumor growth and resistance to apoptosis in cervical carcinoma HeLa cells through AKT. 2011 PLoS ONE 6(5):e19679. PubMed
El Fajoui Z, Toscano F, Jacquemin G, Abello J, Scoazec JY, Micheau O, Saurin JC Oxaliplatin Sensitizes Human Colon Cancer Cells to TRAIL through JNK-Dependent Phosphorylation of Bcl-xL. 2011 Gastroenterology ;141(2):663-73. PubMed
Morizot A, Merino D, Lalaoui N, Granci V, Jacquemin G, Lanneau D, Iessi L, Solary E, Chauffert B, Saas P, Garrido C, Micheau O Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level. 2011 Cell Death Differ. 18(4):700-11. PubMed
Rérole AL, Gobbo J, Schmitt E, Pais de Barros JP, Lanneau D, De Thonel A, Hammann A, Fourmaux E, Deminov O, Micheau O, Lagrost L, Colas P, Kroemer G and Garrido C. Peptides and aptamers targeting HSP70: a novel approach for anti-cancer chemotherapy. 2011 Cancer Res. 71(2):484-95. PubMed
Shirley S. and Micheau O The heme oxygenase-1 and c-FLIP in acute myeloid leukemias: two non-redundant but mutually exclusive cellular safeguards protecting cells against TNF-induced cell death? 2010 Oncotarget. 1(5):317-9. PubMed
Jacquemin G, Shirley S, Micheau O Combining naturally occurring polyphenols with TNF-related apoptosis-inducing ligand: a promising approach to kill resistant cancer cells? 2010 Cell Mol Life Sci. 67(18):3115-30. PubMed
Pavet V, Beyrath J, Pardin C, Morizot A, Lechner MC, Briand JP, Wendland M, Maison W, Fournel S, Micheau O, Guichard G, Gronemeyer H Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity in vivo. 2010 Cancer Res 70(3):1101-1110. PubMed
Fraszczak J, Trad M, Janikashvili N, CathelinD, Lakomy D, Granci V, Morizot A, Audia S, Micheau O, Lagrost L, Katsanis E, Solary E, Larmonier N, Bonnotte B Peroxynitrite-Dependent Killing of Cancer Cells and Presentation of Released Tumor Antigens by Activated Dendritic Cells. J Immunol. 2010 ;184(4):1876-84. PubMed
Lalaoui N, Audo R, Morel J, Micheau O, Hahne M Where ends the TRAIL in arthritis? 2009 Rheumatology Reports 1(1):32-36. PubMed
Jacquel A, Benikhlef N, Paggetti J, Lalaoui N, Guery L, Dufour EK, Ciudad M, Racoeur C, Micheau O, Delva L, Droin N, Solary E CSF-1-induced oscillations in PI3K/AKT are required for caspase activation in monocytes undergoing differentiation into macrophages. 2009 Blood 114(17): 3633-3641. PubMed
Rushworth SA, Micheau O Molecular crosstalk between TRAIL and natural antioxidants in the treatment of cancer. 2009 Br J Pharmacol. 157(7):1186-1188. PubMed
Kassahn D, Nachbur U, Conus S, Micheau o, Schneider P, Simon H-U, Brunner T Distinct requirements for activation-induced cell surface expression of preformed Fas/CD95 ligand and cytolytic granule markers in T cells. 2009 Cell Death Differ. 16(1):115-124. PubMed
Ndozangue-Touriguine O, Sebbagh M, Mérino D, Micheau O, Bertoglio J, Bréard J A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma. 2008 Oncogene 27(46):6012-22. PubMed
TraverTravert M, Ame-Thomas P, Pangault C, MorizotA, Micheau O, Semana G, Lamy T, Fest T, Tarte K, Guillaudeux T CD40 Ligand Protects from TRAIL-Induced Apoptosis in Follicular Lymphomas through NF-kappa B Activation and Up-Regulation of c-FLIP and Bcl-xL. 2008 J. Immunol. 181(2):1001-1011. PubMed
Toscano F, El Fajoui Z, Gay F, Lalaoui N, Parmentier B, Chayvialle JA, Scoazec JY, Micheau O, Abello J,Saurin JC p53-mediated up-regulation of DcR1 impairs oxaliplatin/TRAILinduced synergistic anti-tumour potential in colon cancer cells. 2008 Oncogene 27(30):4161-71. PubMed
Mérino D, Lalaoui N, Morizot A, Solary E, Micheau O TRAIL in cancer therapy: current and future challenges. 2007 Expert Opin. Ther. Targets 11(10), 1299-1314. PubMed
Brahim S, Prévotat L, Yatouji S, Mérino D, Cortier M, Rébé C, Micheau O, Kenani A, Bettaieb A Deglycosylated Bleomycin induces apoptosis in Lymphoma cell via c-jun NH2-terminal kinase but not reactiveoxygen species. 2007 Biochem Pharmacol. 74(10), 1445-55. PubMed
Grobner S Adkins I, Schulz S, Richter K, Borgmann S, Wesselborg S, Ruckdeschel K, Micheau O, Autenrieth IB, Catalytically active Yersinia outer protein P induces cleavage of RIP and caspase-8 at the level of the DISC independently of death receptors in dendritic cells. 2007 Apoptosis 12(10):1813-25. PubMed
Kummer* JA, Micheau* O, Schneider P, Bovenschen N, Broekhuizen R, Quadir R, Strik MCL, Hack E, Tschopp J, Ectopic expression of the serine protease inhibitor PI9 modulates death receptor -mediated apoptosis. 2007 Cell Death Differ. 14(8), 1486-96. PubMed. Equal contribution*.
Meurette O, Huc L, Rebillard A, Le Moigne G, Merino D, Micheau O, Lagadic-Gossmann D, Dimanche Boitrel MT TRAIL induces a RIP1 (Receptor-Interacting Protein 1)-dependent and caspase dependent necrosis-like cell death under acidic extra-cellular conditions (pH 6.5). 2007 Cancer Res. 67(1), 218-226. PubMed
Rébé C, Cathelin S, Launay S, Filomenko R, Prévotat L, L’Ollivier C, Gyan E, Micheau O, Grant S, Dubart-Kupperschmitt A, Fontenay M, Solary E, Caspase-8 prevents sustained activation of NF-κB in monocytes undergoing macrophagic differentiation. 2007 Blood, 109(4):1442-50. PubMed
Mérino D, Lalaoui N, Morizot A, Solary E, Schneider P, Micheau O, Differential inhibition of TRAIL-induced apoptosis by DcR1 and DcR2. 2006 Mol. Cell. Biol. 26(19):7046-7055. PubMed
Burron N, Micheau O, Lafontaine PO, Creuzot-Gracher C, Solary E Differential mechanisms of conjunctival cell death induction by ultraviolet and benzalkonium chloride. 2006 IOVS. 47(10):4221-4230. PubMed
Micheau O, Cellular FLICE-inhibitory Protein: An Update. 2006 Apoptosis and Cancer Therapy. Ed K-M Debatin and S Fulda. Wiley-VCH Verlag GmbH & Co. KGaA, 120-155. Wiley-VCH
Lemarie A, Morzadec C, Mérino D, Micheau O, Fardel O and Vernhet L, Arsenic trioxide inhibits macrophagic differentiation at clinically relevant concentrations through NF-kB-related survival pathway downregulation. 2006 J Pharmacol Exp Ther. 316(1):304-14. PubMed
Salon C, Eymin B, Micheau O, Chaperot L, Plumas J, Brambilla C, Brambilla E, Gazzeri S, E2F1 induces apoptosis and sensitize human cell lung carcinoma through specific downregulation of the FLIP short protein isoform. 2006 Cell Death Differ. 13(2):260-72. PubMed
Delmas D, Rebe C, Micheau O, Athias A, Gambert P, Grazide S, Laurent G, Latruffe N, Solary E. Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. 2004 Oncogene. 23(55):8979-86. PubMed
Micheau O., Mérino D., Controlling TRAIL-mediated caspase-3 activation. 2004 Leukemia, 18(10):1578-80. PubMed
Micheau O., To die or not to die ? Un modele de la signalisation dichotomique de TNF-R1. 2004 Médecine et Sciences, 20 (2) :153-5. (French) PubMed
Micheau O., Interference ARN, une nouvelle ere post-genomique ?: L'exemple par TRAIL. 2004 Médecine et Sciences (Brève), 20 (2) :163. (French) PubMed
Micheau O. and J. Tschopp Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. 2003 Cell 114(2) :181- 190. PubMed
Micheau O. Cellular FLICE-inhibitory protein : an attracive therapeutic target ?. 2003 Expert Opin. Ther. Targets. 7(4):559-73. PubMed
Viard-Leveugle I., Bullani R., Meda P., Micheau O., Limat A., Saurat J.H., Tschopp J. and French L.E. Intracellular localization of keratinocyte Fas ligand explains lack of cytolytic activity under physiological conditions. 2003 J. Biol. Chem. 278(18):16183-88 . PubMed
Micheau O*., Lacours S*., Hammann A., Drouineaud V., Tschopp J., Solary E., Dimanche-Boitrel M.T. Chemotherapy enhances TNF-related apoptosis-inducing Ligand DISC assembly in HT29 human colon cancer cells. 2003 Oncogene, 22(12): 1807-1816. Equal contribution*. PubMed
Legler D.F., Micheau O., Doucey M.A., Tschopp J., Bron C. Lipid rafts are essential for TNF±-mediated TNFR1/RIP ubiquitination and NF-kB activation. 2003 Immunity.18(5):655-64 . PubMed
Micheau O., Thome M., Schneider P., Holler N., Tschopp J., Nicholson D., Briand C., Grutter M.G.The long form of FLIP is an activator of Caspase-8 at the Fas death-inducing signaling complex. 2002 J. Biol. Chem. 277(47):45162-71. PubMed
Ducoroy P., Micheau O., Dubrez-Daloz L., Annat J., de Fornel D., Solary E. LF-15-0195 immunosuppressive agent enhances actvation-induced T-Cell death by facilitating caspase-8 activation at the DISC level. 2002 Blood. 101(1): 194-201. PubMed
Kovacsovics M., Martinon F., Micheau O., Bodmer JL., Hofmann K. and Tschopp J. Overexpression of Helicard, a CARD-Containing Helicase Cleaved during Apoptosis, Accelerates DNA Degradation. 2002 Cur. Biol., 12(10):838-843. PubMed
Micheau O., Lens S., Gaide O., Alevizopoulos K., Tschopp J. NF-kappaB Signals Induce the Expression of c-FLIP. 2001 Mol. Cell. Biol. 21(16):5299-5305. PubMed
Gaide O, Martinon F, Micheau O, Bonnet D, Thome M, Tschopp J. Carma1, a CARD-containing binding partner of Bcl10, induces Bcl10 phosphorylation and NF-kappaB activation. 2001 FEBS Lett. 496(2-3):121-127. PubMed
Kataoka T, Holler N, Micheau O, Martinon F, Tinel A, Hofmann K, Tschopp J. Bcl-rambo, a novel Bcl-2 homologue that induces apoptosis via its unique C-terminal extension. 2001 J. Biol. Chem. 276(22):19548-19554. PubMed
Thome M., Gaide O., Micheau O., Martinon F., Bonnet D., Gonzalez M., Tschopp J. Equine Herpesvirus Protein E10 Induces Membrane Recruitment and Phosphorylation of its Cellular Homologue, Bcl-10. 2001 J. Cell Biol. 152(5):1115-1122. PubMed
Holler N., Zaru R., Micheau O., Thome M., Attinger A., Valitutti S., Bodmer J.L., Schneider P., Seed B., Tschopp J. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule, 2000 Nat. Immunol. 1(6): 449 - 541. PubMed
Rochat-Steiner V, Becker K, Micheau O., Schneider P., Burns K., Tschopp J. FIST/HIPK3: a Fas/FADD interacting serine/threonine kinase that induces FADD phosphorylation and inhibits Fas-mediated Jun N-terminal kinase activation, 2000 J. Exp. Med. 192(8):1165-74. PubMed
Dimanche-Boitrel M.T., Micheau O., France D., Hammann A., Duchamp O., Genne P., Solary E. P27KiP1 overexpression inhibits the growth and doxorubicin sensitivity of HT29 human colon cancer cells in vivo. 2000 Anticancer Res. 20(2A):849-52. PubMed
Micheau O., Solary E., Hammann A., Dimanche-Boitrel M.T.,STAT-1-independent upregulation of FADD and procaspase-3 and -8 in cancer cells treated with cytotoxic drugs. 1999 Biochem Biophys Res Commun. 256(3):603-7. PubMed
Dimanche-boitrel M.T., Micheau O., Solary E. Fas est implique dans l'apoptose induite par les agents anticancereux independamment de toute interaction avec son ligand. 1999 Medecine et Sciences, 15 :895-6. (French) PubMed
Micheau O., Solary E., Hammann A., Dimanche-Boitrel M.T., Fas-ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs, 1999 J. Biol. Chem. 274(12):7987-92. PubMed
Solary E., Micheau O., Martin F., Dimanche-Boitrel M.T., Martin F., Le systeme Fas/Fas ligand: implication dans la reponse immunitaire antitumorale et la resistance aux agents cytotoxiques, 1998 Bulletin du Cancer. 85(8):685-94. PubMed
Dimanche-Boitrel M.T., Micheau O., Hammann A., Haugg M., Eymin B., Chauffert B, Solary E., Contribution of the cyclin-dependent kinase inhibitor p27KIP1 to the confluence-dependent resistance of colon carcinoma HT29 cells. 1998 Int. J. Cancer 77(5):796-802. PubMed
Bonnotte B., Favre N., Reveneau S., Micheau O., Droin N., Garrido C., Fontana A., Chauffert B., Solary E., Martin F. Cancer cell sensitization to fas-mediated apoptosis by sodium butyrate. 1998 Cell Death Differ. 1998;5(6):480-7. PubMed
Micheau O., Solary E., Hammann A., Martin F., Dimanche-Boitrel M.T., Sensitization of Cancer Cells Treated With Cytotoxic Drugs to Fas-Mediated Cytotoxicity. 1997 J. Natl. Cancer Inst. 89(11):783-9. PubMed